Acacia Pharma - Two US drug launches in 2020
Operationally, the year to date, has been exceptional in Acacia Pharma’s history. It achieved significant milestones with two US FDA approvals: BARHEMSYS (amisulpride injection) for the management of post-operative nausea and vomiting (PONV) on 26 February and BYFAVO (remimazolam), an intravenous benzodiazepine sedative for use during invasive medical procedures on 6 July. Acacia has evolved into an integrated hospital pharmaceutical company with strong development and commercialisation capabilities. Management’s focus is now on executing the successful launch of both assets in H220 and Acacia recently raised €25m gross proceeds in a share placing to fund this; timely launches and the effective sales execution of both products is critical. We value Acacia at $989m.Acacia Pharma Group Plc. Acacia Pharma Group PLC is a United Kingdom-based company specialized in the pharmaceutical industry. The pharmaceutical group focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. Its pipeline includes BAREMIS, an intravenous formulation of amisulpride, which is a selective dopamine antagonist that has completed phase 3 clinical development for the prophylaxis and treatment of Postoperative nausea and vomiting (PONV), and APD403, which is based on the selective dopamine antagonist amisulpride and it is being developed as an intravenous injection for cancer patients to be administered immediately before chemotherapy to prevent acute chemotherapy-induced nausea & vomiting ( CINV).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.